CompletedPhase 2NCT05436639
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Studying NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sparrow Pharmaceuticals
- Principal Investigator
- Frank Czerwiec, MDSparrow Pharmaceuticals
- Intervention
- SPI-62 dose(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (5)
- Mayo Clinic Cancer Center (MCCC) - Rochester, Rochester, Minnesota, United States
- Ohio State McCampbell Outpatient Care, Columbus, Ohio, United States
- C.M.D.T.A. Neomed, Brasov, Romania
- Institutul National de Endocrinologie, Bucharest, Romania
- King's College Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05436639 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07361874IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE4NCT07247058Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)Johns Hopkins University
- RECRUITINGPHASE2NCT07104812Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT06106295Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
See all trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor →